{"protocolSection":{"identificationModule":{"nctId":"NCT00163150","orgStudyIdInfo":{"id":"A2581063"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke","officialTitle":"Lacunar-Brain Infarction Cerebral Hyperactivity And Atorvastatin Trial. A Placebo-Controlled Trial Of High-Dose Atorvastatin In Patients With Cerebral Small Vessel Disease.","acronym":"LA BICHAT"},"statusModule":{"statusVerifiedDate":"2021-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2003-06"},"completionDateStruct":{"date":"2006-02","type":"ACTUAL"},"studyFirstSubmitDate":"2005-09-09","studyFirstSubmitQcDate":"2005-09-09","studyFirstPostDateStruct":{"date":"2005-09-13","type":"ESTIMATED"},"lastUpdateSubmitDate":"2021-02-17","lastUpdatePostDateStruct":{"date":"2021-02-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients."},"conditionsModule":{"conditions":["Cerebrovascular Accident","Hypercholesterolemia"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE"}},"enrollmentInfo":{"count":128}},"armsInterventionsModule":{"interventions":[{"type":"DRUG","name":"Atorvastatin"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients. CVR, humeral and carotid vasoreactivity will be measured in all patients at M0 and M3."}],"secondaryOutcomes":[{"measure":"Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on endothelium dependant and independent vasomotoricity of humeral and / or common carotid artery (according to validation study) in lacunar patients."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* clinically defined lacunar syndrome 3 months before inclusion\n* small deep infarct on diffusion MRI (Diffusion Weighted Imaging)\n* no atherothrombotic, cardio-embolic, or other rarer cause.\n\nExclusion Criteria:\n\n* patients with past coronary event\n* contra-indication for assessment of vasomotor reactivity\n* patients being on statin therapy at the time of brain infarction\n* contra-indication for statin therapy\n* patient still under statin therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Pfizer Investigational Site","city":"Paris, Cedex 18","zip":"75877","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}}]},"referencesModule":{"references":[{"pmid":"19286582","type":"DERIVED","citation":"Lavallee PC, Labreuche J, Gongora-Rivera F, Jaramillo A, Brenner D, Klein IF, Touboul PJ, Vicaut E, Amarenco P; Lacunar-BICHAT Investigators. Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease. Stroke. 2009 May;40(5):1721-8. doi: 10.1161/STROKEAHA.108.540088. Epub 2009 Mar 12."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A2581063&StudyName=Vasomotor+Reactivity+In+Cerebral+Small+Vessel+Disease+And+New+Approach+To+Treat+Lacunar+Stroke+"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000059345","term":"Cerebral Small Vessel Diseases"},{"id":"D000006937","term":"Hypercholesterolemia"}],"ancestors":[{"id":"D000006949","term":"Hyperlipidemias"},{"id":"D000050171","term":"Dyslipidemias"},{"id":"D000052439","term":"Lipid Metabolism Disorders"},{"id":"D000008659","term":"Metabolic Diseases"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Cerebrovascular Accident","relevance":"HIGH"},{"id":"M9689","name":"Hyperkinesis","relevance":"LOW"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","relevance":"LOW"},{"id":"M29127","name":"Cerebral Small Vessel Diseases","asFound":"Cerebral Small Vessel Disease","relevance":"HIGH"},{"id":"M9678","name":"Hypercholesterolemia","asFound":"Hypercholesterolemia","relevance":"HIGH"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M29153","name":"Stroke, Lacunar","relevance":"LOW"},{"id":"M9690","name":"Hyperlipidemias","relevance":"LOW"},{"id":"M9692","name":"Hyperlipoproteinemias","relevance":"LOW"},{"id":"M25871","name":"Dyslipidemias","relevance":"LOW"},{"id":"M11329","name":"Metabolic Diseases","relevance":"LOW"},{"id":"M26719","name":"Lipid Metabolism Disorders","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069059","term":"Atorvastatin"}],"ancestors":[{"id":"D000000924","term":"Anticholesteremic Agents"},{"id":"D000000960","term":"Hypolipidemic Agents"},{"id":"D000000963","term":"Antimetabolites"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000057847","term":"Lipid Regulating Agents"},{"id":"D000019161","term":"Hydroxymethylglutaryl-CoA Reductase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"}],"browseLeaves":[{"id":"M351","name":"Atorvastatin","asFound":"Functional","relevance":"HIGH"},{"id":"M3933","name":"Anticholesteremic Agents","relevance":"LOW"},{"id":"M3968","name":"Hypolipidemic Agents","relevance":"LOW"},{"id":"M3971","name":"Antimetabolites","relevance":"LOW"},{"id":"M28573","name":"Lipid Regulating Agents","relevance":"LOW"},{"id":"M20845","name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Lipd","name":"Lipid Regulating Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}